Income Statement (TTM)
MediXall Group, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 09-30 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | 657.18 | 5,094.53 | 2.22 | -91.37 | 30.92 | -796.14 | -12.43 | -149.53 | 118.04 | 47.34 | 23.51 | 31.57 | 13.02 | -5.34 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 3 | 2 | 2 | 2 | 3 | 4 | 4 | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 1 |
| Change (%) | -13.31 | 3.41 | 4.66 | 30.55 | 30.28 | 2.54 | -6.35 | -16.63 | -36.43 | -26.39 | -3.19 | -14.30 | -11.66 | -6.12 | |
| % of Revenue | 579,547.22 | 66,352.03 | 1,320.91 | 1,352.38 | 20,449.52 | 20,349.50 | -2,997.54 | -3,205.92 | 5,396.21 | 1,573.24 | 786.00 | 616.10 | 401.30 | 313.69 | 311.11 |
| Gross Operating Profit | -3 | -2 | -2 | -2 | -3 | -4 | -4 | -4 | -3 | -2 | -1 | -1 | -1 | -1 | -1 |
| Change (%) | -13.43 | -4.27 | 4.86 | 40.28 | 30.27 | 6.49 | -6.54 | -20.65 | -39.35 | -31.39 | -7.08 | -23.19 | -19.85 | -6.49 | |
| % of Revenue | -579,447.22 | -66,252.03 | -1,220.91 | -1,252.38 | -20,349.52 | -20,249.50 | 3,097.54 | 3,305.92 | -5,296.21 | -1,473.24 | -686.00 | -516.10 | -301.30 | -213.69 | -211.11 |
| SG&A | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 |
| Change (%) | -4.70 | 23.10 | 10.03 | -6.22 | 4.62 | -10.42 | -0.97 | 8.75 | -1.65 | -0.30 | -3.65 | -6.08 | -21.06 | -21.99 | |
| % of Revenue | 636,996.30 | 80,176.22 | 1,900.02 | 2,045.19 | 22,216.62 | 17,754.65 | -2,284.74 | -2,583.87 | 5,673.44 | 2,559.19 | 1,731.78 | 1,350.91 | 964.33 | 673.56 | 555.11 |
| R&D | |||||||||||||||
| Change (%) | |||||||||||||||
| % of Revenue | |||||||||||||||
| OpEx | 5 | 5 | 6 | 7 | 6 | 7 | 7 | 7 | 6 | 5 | 5 | 4 | 4 | 3 | 3 |
| Change (%) | 3.06 | 12.55 | 7.03 | -2.20 | 16.96 | -3.50 | -4.03 | -7.69 | -19.13 | -10.59 | -3.64 | -4.94 | -18.30 | -16.95 | |
| % of Revenue | 1,216,543.52 | 165,592.14 | 3,587.93 | 3,756.60 | 42,556.11 | 38,020.10 | -5,270.21 | -5,776.00 | 10,765.08 | 3,992.75 | 2,422.97 | 1,890.26 | 1,365.64 | 987.25 | 866.22 |
| Operating Income | -5 | -5 | -6 | -6 | -6 | -7 | -7 | -7 | -6 | -5 | -4 | -4 | -4 | -3 | -3 |
| Change (%) | 3.01 | 9.48 | 7.16 | 0.24 | 16.93 | -1.41 | -4.19 | -10.11 | -20.42 | -12.08 | -4.81 | -6.98 | -20.77 | -18.26 | |
| % of Revenue | -1,216,443.52 | -165,492.14 | -3,487.93 | -3,656.60 | -42,456.11 | -37,920.10 | 5,370.21 | 5,876.00 | -10,665.08 | -3,892.75 | -2,322.97 | -1,790.26 | -1,265.64 | -887.25 | -766.22 |
| Interest Expense | -0 | -0 | -0 | -0 | -1 | -1 | -1 | ||||||||
| Change (%) | 37.58 | 8.83 | 9.11 | 46.12 | 12.14 | 10.04 | |||||||||
| % of Revenue | -457.44 | -288.65 | -213.21 | -188.36 | -209.18 | -207.56 | -241.29 | ||||||||
| Net Income | -5 | -5 | -6 | -6 | -6 | -7 | -7 | -7 | -7 | -6 | -5 | -5 | -5 | -4 | -3 |
| Change (%) | 3.01 | 9.48 | 7.16 | -2.37 | 17.38 | -1.45 | -4.28 | -0.52 | -17.40 | -10.18 | -3.47 | -6.71 | -16.10 | -12.89 | |
| % of Revenue | -1,216,443.52 | -165,492.14 | -3,487.93 | -3,656.60 | -41,350.94 | -37,075.93 | 5,248.94 | 5,737.52 | -11,524.63 | -4,365.81 | -2,661.35 | -2,079.95 | -1,474.82 | -1,094.80 | -1,007.51 |
Source: Capital IQ
